Asciminib for HER2+ breast cancer that has spread to the brain
Part of Brain & nervous system, Cancer clinical trials.
This trial tests the drug asciminib for people with HER2-positive breast cancer that has spread to the brain and is growing. It may be an option if you have already tried standard treatments like T-DXd and tucatinib.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have HER2-positive breast cancer that has spread to the brain and at least one brain tumor that is growing or new, larger than 5mm.
- You have had at least one prior treatment for metastatic breast cancer.
- You have already received T-DXd and tucatinib, unless you couldn't take them due to allergies or side effects.
- You have adequate organ function (kidney, liver, heart, and blood cell counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (adebrelimab and apatinib) plus chemotherapy for women with HER2-negative breast cancer that has spread to the brain. It aims to see if this treatment can help shrink or control brain tumors.
This Phase 2 study tests tucatinib plus T-DM1 (ado-trastuzumab emtansine) in people with HER2-positive metastatic solid tumors that have spread to the brain. It aims to shrink brain and body tumors and help control cancer that is progressing in the brain.
This trial tests how well an imaging test can predict the effectiveness of the drug T-DXd in people with HER2-positive breast cancer that has spread to the brain. It aims to see if a special scan can help guide treatment.
This trial tests whether adding neratinib to T-DXd (trastuzumab deruxtecan) works better than T-DXd alone for women with HER2-positive breast cancer that has spread to the brain. It is for those who have not had these specific drugs before.
This trial tests a combination of two targeted drugs (T-DXd and bevacizumab) for people with HER2-low breast cancer that has spread to the brain. It aims to see if adding bevacizumab helps the main drug work better against brain metastases.
This trial is testing a combination of a targeted drug (Sacituzumab Govitecan) and radiation to the head for people with HER2-negative breast cancer that has spread to the brain. The goal is to see if this combination can help shrink brain tumors and improve outcomes.
Hear when a new HER2+ Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.